 Lilliam Ambroggio
Concepts (301)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 45 | 2026 | 174 | 13.040 |
Why?
| | Pneumonia | 46 | 2026 | 631 | 11.520 |
Why?
| | Anti-Bacterial Agents | 29 | 2026 | 1915 | 4.540 |
Why?
| | Emergency Service, Hospital | 28 | 2026 | 2313 | 3.000 |
Why?
| | Pneumonia, Bacterial | 10 | 2025 | 113 | 2.730 |
Why?
| | Respiratory Tract Infections | 14 | 2026 | 398 | 2.350 |
Why?
| | Child | 103 | 2026 | 22657 | 2.170 |
Why?
| | Infant | 59 | 2026 | 10039 | 1.790 |
Why?
| | Child, Preschool | 59 | 2026 | 11799 | 1.700 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2925 | 1.680 |
Why?
| | Hospitalization | 24 | 2026 | 2434 | 1.490 |
Why?
| | Guideline Adherence | 5 | 2023 | 589 | 1.480 |
Why?
| | Macrolides | 4 | 2021 | 69 | 1.420 |
Why?
| | Pneumonia, Mycoplasma | 5 | 2025 | 55 | 1.400 |
Why?
| | Ultrasonography | 3 | 2024 | 770 | 1.390 |
Why?
| | Wounds, Gunshot | 3 | 2026 | 258 | 1.380 |
Why?
| | Length of Stay | 11 | 2025 | 1337 | 1.340 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 557 | 1.290 |
Why?
| | Quality Improvement | 8 | 2025 | 1291 | 1.280 |
Why?
| | beta-Lactams | 3 | 2015 | 32 | 1.270 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 47 | 1.230 |
Why?
| | Streptococcus pneumoniae | 3 | 2025 | 177 | 1.150 |
Why?
| | Firearms | 3 | 2026 | 435 | 1.120 |
Why?
| | Propensity Score | 5 | 2025 | 367 | 1.050 |
Why?
| | Asthma | 6 | 2023 | 1768 | 1.040 |
Why?
| | Biomedical Research | 4 | 2023 | 710 | 1.030 |
Why?
| | Humans | 118 | 2026 | 144957 | 1.020 |
Why?
| | Prospective Studies | 34 | 2025 | 7997 | 1.010 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1563 | 1.000 |
Why?
| | Bacteremia | 4 | 2019 | 221 | 0.980 |
Why?
| | Retrospective Studies | 34 | 2026 | 17101 | 0.960 |
Why?
| | Adolescent | 47 | 2026 | 22453 | 0.920 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 127 | 0.860 |
Why?
| | Patient Readmission | 6 | 2026 | 759 | 0.840 |
Why?
| | Male | 64 | 2026 | 72406 | 0.830 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 119 | 0.830 |
Why?
| | Credentialing | 1 | 2024 | 21 | 0.830 |
Why?
| | Administration, Oral | 6 | 2026 | 848 | 0.810 |
Why?
| | Outpatients | 4 | 2024 | 443 | 0.790 |
Why?
| | Suicide | 3 | 2025 | 720 | 0.780 |
Why?
| | Female | 65 | 2026 | 78376 | 0.770 |
Why?
| | Mycoplasma pneumoniae | 7 | 2025 | 53 | 0.770 |
Why?
| | Thiamine Deficiency | 1 | 2022 | 9 | 0.740 |
Why?
| | Radiography, Thoracic | 4 | 2022 | 171 | 0.730 |
Why?
| | Point-of-Care Systems | 1 | 2024 | 187 | 0.710 |
Why?
| | Communicable Diseases | 1 | 2023 | 163 | 0.690 |
Why?
| | Evidence-Based Medicine | 2 | 2015 | 732 | 0.680 |
Why?
| | Ambulatory Care | 5 | 2025 | 603 | 0.630 |
Why?
| | Administration, Intravenous | 3 | 2025 | 170 | 0.620 |
Why?
| | Mental Health Services | 1 | 2025 | 474 | 0.620 |
Why?
| | Microbiota | 5 | 2026 | 781 | 0.570 |
Why?
| | Patient Discharge | 3 | 2022 | 983 | 0.570 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 249 | 0.560 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 479 | 0.550 |
Why?
| | Sepsis | 3 | 2022 | 641 | 0.540 |
Why?
| | Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.530 |
Why?
| | Drug Prescriptions | 3 | 2020 | 285 | 0.520 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 81 | 0.520 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2017 | 27 | 0.510 |
Why?
| | Mass Screening | 3 | 2024 | 1348 | 0.500 |
Why?
| | Pediatrics | 4 | 2024 | 1115 | 0.490 |
Why?
| | Viruses | 3 | 2023 | 165 | 0.480 |
Why?
| | Research Design | 4 | 2021 | 1137 | 0.470 |
Why?
| | Alcoholism | 1 | 2022 | 817 | 0.450 |
Why?
| | Biomarkers | 11 | 2025 | 4275 | 0.440 |
Why?
| | Child, Hospitalized | 4 | 2024 | 55 | 0.420 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 54 | 0.410 |
Why?
| | Treatment Failure | 3 | 2024 | 365 | 0.400 |
Why?
| | Research | 2 | 2016 | 431 | 0.390 |
Why?
| | ROC Curve | 4 | 2025 | 615 | 0.390 |
Why?
| | Clinical Decision-Making | 4 | 2022 | 359 | 0.390 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 57 | 0.370 |
Why?
| | Adrenomedullin | 2 | 2021 | 5 | 0.350 |
Why?
| | Virus Diseases | 2 | 2024 | 216 | 0.350 |
Why?
| | Metabolomics | 3 | 2025 | 727 | 0.320 |
Why?
| | Fever | 3 | 2022 | 312 | 0.310 |
Why?
| | Respiratory Sounds | 3 | 2022 | 105 | 0.310 |
Why?
| | Odds Ratio | 3 | 2022 | 1077 | 0.310 |
Why?
| | Hospital Charges | 1 | 2009 | 46 | 0.300 |
Why?
| | Prognosis | 7 | 2023 | 4293 | 0.300 |
Why?
| | Simplexvirus | 1 | 2009 | 82 | 0.300 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2025 | 631 | 0.290 |
Why?
| | United States | 12 | 2024 | 15988 | 0.290 |
Why?
| | Herpes Simplex | 1 | 2009 | 98 | 0.290 |
Why?
| | Critical Illness | 6 | 2025 | 892 | 0.280 |
Why?
| | Health Resources | 1 | 2009 | 130 | 0.280 |
Why?
| | Pandemics | 4 | 2024 | 1695 | 0.280 |
Why?
| | Cohort Studies | 12 | 2025 | 5965 | 0.270 |
Why?
| | Suicidal Ideation | 2 | 2025 | 577 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2024 | 11695 | 0.270 |
Why?
| | Utilization Review | 2 | 2018 | 39 | 0.250 |
Why?
| | Feces | 2 | 2021 | 513 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2025 | 3608 | 0.250 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1048 | 0.250 |
Why?
| | Bacteria | 5 | 2026 | 889 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1358 | 0.240 |
Why?
| | Risk Factors | 10 | 2025 | 10792 | 0.240 |
Why?
| | Penicillins | 2 | 2023 | 61 | 0.230 |
Why?
| | Ohio | 2 | 2016 | 145 | 0.230 |
Why?
| | Caregivers | 2 | 2026 | 1049 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 372 | 0.230 |
Why?
| | Serogroup | 1 | 2025 | 44 | 0.230 |
Why?
| | Carrier State | 1 | 2026 | 79 | 0.230 |
Why?
| | Amoxicillin | 1 | 2025 | 35 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1721 | 0.220 |
Why?
| | Inpatients | 2 | 2021 | 546 | 0.220 |
Why?
| | Influenza, Human | 2 | 2023 | 617 | 0.220 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 68 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2025 | 112 | 0.210 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 75 | 0.210 |
Why?
| | Asymptomatic Infections | 1 | 2024 | 37 | 0.210 |
Why?
| | Protein Precursors | 2 | 2021 | 137 | 0.210 |
Why?
| | Infant, Newborn | 7 | 2025 | 6434 | 0.210 |
Why?
| | Critical Pathways | 1 | 2025 | 108 | 0.210 |
Why?
| | Trachea | 1 | 2026 | 261 | 0.210 |
Why?
| | Diagnostic Errors | 1 | 2025 | 175 | 0.200 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 285 | 0.200 |
Why?
| | Logistic Models | 4 | 2021 | 2119 | 0.190 |
Why?
| | Nervous System Diseases | 2 | 2016 | 284 | 0.190 |
Why?
| | Family Characteristics | 1 | 2024 | 197 | 0.190 |
Why?
| | Pennsylvania | 2 | 2015 | 138 | 0.190 |
Why?
| | Pneumonia, Aspiration | 2 | 2019 | 16 | 0.190 |
Why?
| | Health Education | 1 | 2026 | 358 | 0.180 |
Why?
| | Thiamine | 1 | 2022 | 18 | 0.180 |
Why?
| | Coinfection | 1 | 2024 | 141 | 0.180 |
Why?
| | Delphi Technique | 1 | 2024 | 331 | 0.180 |
Why?
| | Consensus | 1 | 2024 | 489 | 0.180 |
Why?
| | Follow-Up Studies | 4 | 2022 | 5417 | 0.180 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 136 | 0.170 |
Why?
| | Pleural Effusion | 1 | 2022 | 60 | 0.170 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 914 | 0.170 |
Why?
| | Suicide, Attempted | 1 | 2025 | 422 | 0.170 |
Why?
| | Nucleic Acids | 1 | 2022 | 72 | 0.170 |
Why?
| | Arthritis, Infectious | 1 | 2022 | 72 | 0.170 |
Why?
| | Blood Culture | 2 | 2019 | 25 | 0.170 |
Why?
| | Safety | 1 | 2023 | 356 | 0.170 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 23 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 224 | 0.160 |
Why?
| | Quality of Life | 2 | 2023 | 3192 | 0.160 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 233 | 0.160 |
Why?
| | Gastroenteritis | 1 | 2021 | 63 | 0.160 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 221 | 0.160 |
Why?
| | International Cooperation | 1 | 2021 | 198 | 0.160 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2019 | 5 | 0.160 |
Why?
| | Osteomyelitis | 1 | 2022 | 143 | 0.150 |
Why?
| | Proteome | 1 | 2024 | 518 | 0.150 |
Why?
| | State Medicine | 1 | 2019 | 27 | 0.150 |
Why?
| | Societies | 1 | 2019 | 40 | 0.150 |
Why?
| | Clinical Deterioration | 1 | 2019 | 9 | 0.150 |
Why?
| | Intensive Care Units | 3 | 2021 | 916 | 0.150 |
Why?
| | Public Health | 1 | 2024 | 566 | 0.150 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 76 | 0.150 |
Why?
| | Physicians | 2 | 2021 | 940 | 0.150 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2018 | 19 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 74 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2026 | 728 | 0.140 |
Why?
| | Diarrhea | 1 | 2020 | 192 | 0.140 |
Why?
| | Prednisolone | 2 | 2020 | 66 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2019 | 168 | 0.140 |
Why?
| | Infectious Disease Medicine | 1 | 2018 | 12 | 0.140 |
Why?
| | Influenza B virus | 1 | 2018 | 47 | 0.140 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5872 | 0.140 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2018 | 50 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 252 | 0.140 |
Why?
| | Prednisone | 2 | 2020 | 221 | 0.130 |
Why?
| | Observer Variation | 2 | 2016 | 355 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 293 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 216 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 1195 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1890 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2065 | 0.130 |
Why?
| | Immunization Schedule | 1 | 2018 | 187 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 294 | 0.130 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6053 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2018 | 157 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2017 | 307 | 0.120 |
Why?
| | Dexamethasone | 2 | 2020 | 372 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 62 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 206 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 682 | 0.120 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 469 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1172 | 0.120 |
Why?
| | Physical Examination | 1 | 2017 | 240 | 0.120 |
Why?
| | Health Services Research | 1 | 2018 | 396 | 0.120 |
Why?
| | Anaphylaxis | 1 | 2017 | 102 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 140 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 324 | 0.110 |
Why?
| | Emergency Medicine | 1 | 2018 | 261 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 371 | 0.110 |
Why?
| | Hospitalists | 1 | 2019 | 266 | 0.110 |
Why?
| | Azithromycin | 2 | 2025 | 104 | 0.110 |
Why?
| | Inservice Training | 1 | 2015 | 117 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1540 | 0.100 |
Why?
| | Hypoxia | 2 | 2024 | 1199 | 0.100 |
Why?
| | Societies, Medical | 1 | 2018 | 887 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3415 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2018 | 529 | 0.100 |
Why?
| | Palliative Care | 1 | 2021 | 1008 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 458 | 0.100 |
Why?
| | Binomial Distribution | 1 | 2012 | 8 | 0.090 |
Why?
| | Ethics, Research | 1 | 2012 | 32 | 0.090 |
Why?
| | Nasopharynx | 2 | 2023 | 73 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1990 | 0.090 |
Why?
| | Age Factors | 2 | 2022 | 3335 | 0.090 |
Why?
| | Linear Models | 1 | 2015 | 854 | 0.090 |
Why?
| | Penicillin Resistance | 1 | 2012 | 8 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1158 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 189 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 548 | 0.090 |
Why?
| | Medical Informatics | 1 | 2012 | 97 | 0.090 |
Why?
| | Drug Therapy | 1 | 2012 | 80 | 0.090 |
Why?
| | Vulnerable Populations | 1 | 2012 | 177 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 170 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2738 | 0.080 |
Why?
| | Plasma | 1 | 2012 | 225 | 0.080 |
Why?
| | Metagenomics | 2 | 2023 | 181 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2025 | 417 | 0.080 |
Why?
| | Information Systems | 1 | 2009 | 57 | 0.080 |
Why?
| | Acyclovir | 1 | 2009 | 96 | 0.070 |
Why?
| | Health Care Costs | 1 | 2012 | 427 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 349 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3676 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 609 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1054 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2025 | 1495 | 0.060 |
Why?
| | Respiration, Artificial | 2 | 2023 | 708 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 851 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1486 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7183 | 0.060 |
Why?
| | Lung | 3 | 2024 | 4109 | 0.060 |
Why?
| | Chemokine CXCL10 | 1 | 2025 | 39 | 0.060 |
Why?
| | Video Recording | 1 | 2026 | 213 | 0.050 |
Why?
| | Hospital Mortality | 2 | 2020 | 1031 | 0.050 |
Why?
| | Respiratory Rate | 1 | 2024 | 23 | 0.050 |
Why?
| | Arkansas | 1 | 2024 | 21 | 0.050 |
Why?
| | Clinical Competence | 1 | 2012 | 1244 | 0.050 |
Why?
| | Adult | 6 | 2026 | 40506 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 70 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2009 | 768 | 0.050 |
Why?
| | Young Adult | 4 | 2025 | 14126 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 145 | 0.050 |
Why?
| | Canada | 1 | 2024 | 428 | 0.050 |
Why?
| | Cotinine | 1 | 2023 | 79 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Tachypnea | 1 | 2022 | 3 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 526 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 67 | 0.040 |
Why?
| | Smoke | 1 | 2023 | 148 | 0.040 |
Why?
| | Gestalt Theory | 1 | 2021 | 2 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 983 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2024 | 422 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1095 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 169 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2024 | 582 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
| | Feedback | 1 | 2021 | 181 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2021 | 124 | 0.040 |
Why?
| | Calcitonin | 1 | 2020 | 27 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 462 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 199 | 0.040 |
Why?
| | Pneumocystis Infections | 1 | 2019 | 1 | 0.040 |
Why?
| | Heart Rate | 1 | 2024 | 855 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 148 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 366 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 356 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 108 | 0.040 |
Why?
| | Transcriptome | 1 | 2026 | 1046 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 1003 | 0.040 |
Why?
| | Central Venous Catheters | 1 | 2020 | 53 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 284 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1031 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 3082 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 783 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2024 | 384 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2026 | 1786 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 316 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 559 | 0.040 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2018 | 38 | 0.040 |
Why?
| | Data Display | 1 | 2018 | 20 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1490 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1416 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1054 | 0.030 |
Why?
| | Bias | 1 | 2017 | 202 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 326 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 433 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4564 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 853 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 635 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 335 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2019 | 877 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2018 | 672 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2883 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2836 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1982 | 0.020 |
Why?
| | Aged | 2 | 2022 | 25947 | 0.020 |
Why?
| | Primary Health Care | 1 | 2020 | 1734 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 7191 | 0.010 |
Why?
| | Registries | 1 | 2012 | 2385 | 0.010 |
Why?
|
|
Ambroggio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|